Images List Premium Download Classic

Hepatitis A

Hepatitis A-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Treatment of herpes, pseudomonas, staph, and hepatitis
September 14, 2017 - N°20170258861

An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt ...
Combo-hepatitis antigen assays and kits for detection of active hepatitis virus infections
The Regents Of The University Of California
August 24, 2017 - N°20170242010

Disclosed herein are assays, systems, and kits for the detection and diagnosis of hepatitis virus infections in subjects.
Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
Nusirt Sciences, Inc.
August 24, 2017 - N°20170239253

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for ...
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Urea compounds and their use as enzyme inhibitors
Katholieke Universiteit Leuven K.u. Leuven R & D
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Composition for preventing or treating fatty liver diseases
Lg Life Sciences Ltd.
February 09, 2017 - N°20170035776

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively ...
Compositions and methods for detection of hepatitis a virus nucleic acid
Gen-probe Incorporated
January 12, 2017 - N°20170009284

Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of hav rna sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting hav nucleic acid sequences are disclosed.
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical ...
Katholieke Universiteit Leuven K.u. Leuven R & D
October 13, 2016 - N°20160297789

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can ...
Compositions and methods for treating non-alcoholic steatohepatitis
Mochida Pharmaceutical Co., Ltd.
July 28, 2016 - N°20160213639

Compositions and methods for the treatment of non-alcoholic steatohepatitis and related disorders are provided herein, for example in women under 50 or pre-menopausal women.
Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and ...
Asociacion Civil De Estudios Superiores (aces)
July 14, 2016 - N°20160201057

The invention relates to the identification of secreted protein, acidic and rich in cysteine (sparc) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof ...
Treatment of herpes, pseudomonas, staph, and hepatitis
Meritus Corporation
June 02, 2016 - N°20160151436

An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt ...
Antagonists of cb1 receptor
Universite De Bordeaux
May 26, 2016 - N°20160145294

The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; ...
Gene signatures of inflammatory disorders that relate to the liver
Institut National De La Recherche Agronomique
March 10, 2016 - N°20160068890

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most ...
Method of producing therapeutic agent
Institut National De La Recherche Agronomique
March 03, 2016 - N°20160058778

The present invention relates to a therapeutic agent, wherein the therapeutic agent is d-boramine. The therapeutic agent is prepared by mixing l-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid. D-boramine, when administered orally or parenterally in therapeutic quantities, is effective for use in the prevention of cancer that arises from mutations to the brca1 and brca2 genes, i. E., breast ...
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Selective detection of hepatitis a, b, c, d, or e viruses or combination thereof
The Usa, As Represented By The Secretary, Depart- Ment Of Health And Human Services
February 04, 2016 - N°20160032411

Processes and compositions are provided for the detection of hepatitis viruses in a sample. Particular processes and compositions are provided for the selective detection of hdv. Also provided are processes and compositions for the simultaneous detection of two or more hepatitis viruses that for the first time provide rapid, reliable, and simple detection of any known hepatitis vims in a ...
Novel fatty acids and their use in conjugation to biomolecules
The Usa, As Represented By The Secretary, Depart- Ment Of Health And Human Services
February 04, 2016 - N°20160030585

Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other ...
Composition for preventing or treating inflammatory disease
National University Corporation Nagoya University
December 24, 2015 - N°20150366917

A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.
Use of heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis and hepatoma
National Tsing Hua University
December 24, 2015 - N°20150366892

The present invention is directed to a use of a heat shock protein inhibitor in preparing pharmaceutical composition for treating hepatitis by scavenging hepatitis b virus-infected cells. The heat shock protein inhibitor is selected from a group including ver-155008, pifithrin-μ, and pharmaceutical acceptable salts thereof. The present invention is also directed to a use of a heat shock ...
Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and ...
Katholieke Universiteit Leuven K.u.leuven R & D
November 26, 2015 - N°20150336920

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral ...
Compositions and methods that enhance an immune response
Chrontech Pharma Ab
September 10, 2015 - N°20150252084

Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis b core antigen (hbcag) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis b core ...
Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer
Singapore Health Services Pte Ltd
August 20, 2015 - N°20150232943

Disclosed are methods of diagnosing liver cancer in a subject as well as methods of assessing the risk of a subject having chronic hepatitis and liver cirrhosis of developing liver cancer. Also disclosed are kits for the diagnosis of liver cancer.
Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver ...
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
August 13, 2015 - N°20150224106

A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells ...
Loading